Clinical trials
Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials
Below are recruiting relapsed or refractory multiple myeloma (rrmm) clinical trials, each written for real people, not researchers. We’re tracking 1,249 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06871410RecruitingPhase 1
Engineered immune cells for relapsed or refractory AML
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
Buffalo, New YorkAges 18 years+ - NCT06864936Recruiting
Eye scan study for ublituximab in multiple sclerosis
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
Baltimore, MarylandAges 18–65 - NCT06810778RecruitingPhase 1/Phase 2
Duvelisib plus venetoclax for relapsed PTCL
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06735248RecruitingPhase 2
Study testing mRNA vaccine for multiple sclerosis relapse prevention
This study tests whether an mRNA vaccine (mRNA-1195) can help prevent relapses in people with early relapsing multiple sclerosis (MS). It compares the vaccine to a placebo (a shot with no active ingredient) to see if it is safe and effective.
Boston, MassachusettsAges 18–55 - NCT06723457RecruitingPhase 2
Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Chicago, IllinoisAges 18 years+ - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT06675123RecruitingPhase 1
Pacritinib with a BTK inhibitor for mantle cell lymphoma
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
Duarte, CaliforniaAges 18 years+ - NCT06644183RecruitingPhase 1/Phase 2
Triple therapy for relapsed CLL after prior treatments
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06641271Enrolling by invitation
Vagus nerve stimulation with hand exercises for MS
This study tests if vagus nerve stimulation (a mild electrical pulse on the ear) combined with hand exercises can help repair the protective coating of your nerves and improve hand function in multiple sclerosis.
Aurora, ColoradoAges 18–70 - NCT06629428RecruitingEarly Phase 1
Study of ublituximab for walking and movement in multiple sclerosis
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Atlanta, GeorgiaAges 18–55 - NCT06630806RecruitingPhase 1
Study of an injection for relapsed or refractory myeloma
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06609928RecruitingPhase 1
CAR T cell therapy for children with relapsed AML that has FOLR1
This trial tests a special immune cell treatment (CAR T cells) that target a protein called FOLR1 found on some AML cells. It is for children aged 6 or younger whose leukemia has come back or not responded to treatment.
Seattle, WashingtonAges Up to 6 years - NCT06569550Recruiting
Fatigue treatment study for multiple sclerosis
This trial tests a brain stimulation therapy designed to reduce fatigue in people with multiple sclerosis. If you experience moderate to severe fatigue and have a stable medication routine, this study might help determine if a non-invasive treatment can improve your energy levels.
Hvidovre, Capital RegionAges 18–65 - NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+ - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06486779Recruiting
Study of Kesimpta in Greek MS Patients
This study watches how well Kesimpta (ofatumumab) works for people with relapsing multiple sclerosis over time. It collects information from routine doctor visits and scans to see if the treatment is controlling the disease.
Athens, AtticaAges 18–55 - NCT06495593Enrolling by invitationPhase 4
Ocrelizumab's effect on immune cells in lymph nodes in MS
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
San Francisco, CaliforniaAges 18–65 - NCT05962177Recruiting
Study of blood tests and scans in relapsing-remitting MS
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
MontpellierAges 18–59 - NCT06378190RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
Barcelona, BarcelonaAges 18–80 - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06222580RecruitingPhase 1
Combination of two targeted drugs for resistant FLT3-mutated AML
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
Chapel Hill, North CarolinaAges 18 years+ - NCT06006273RecruitingPhase 1
Testing a new drug combo for children with returning solid tumors
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
Houston, TexasAges 1–25 - NCT05958381Recruiting
Brain stimulation for memory problems in relapsing MS
This trial studies a noninvasive brain stimulation treatment to improve memory (specifically memory recall) in people with relapsing-remitting multiple sclerosis (RRMS). It may help if your memory testing shows a “retrieval” problem, and if you’re able to follow the study treatment and safety requirements.
Richardson, TexasAges 18–65 - NCT05848765RecruitingPhase 2
Trial for relapsed follicular lymphoma after prior chemo
This Phase 2 trial studies treatment options for follicular lymphoma that has returned or did not respond to prior therapy. It compares a standard chemotherapy approach against another study treatment to see which works better and is tolerable.
AberdeenAges 18 years+
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma (rrmm)?
- Yes. Clin2 currently lists 1,249 recruiting relapsed or refractory multiple myeloma (rrmm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma (rrmm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma (rrmm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.